As Testosterone Lawsuit Filings Grow, FDA Casts Doubt on Benefits of Low Testosterone Therapy, Bernstein Liebhard LLP Reports - KWES NewsWest 9 / Midland, Odessa, Big Spring, TX: newswest9.com |

As Testosterone Lawsuit Filings Grow, FDA Casts Doubt on Benefits of Low Testosterone Therapy, Bernstein Liebhard LLP Reports

Posted:

This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.

SOURCE:

The Firm is evaluating testosterone treatment lawsuits on behalf of men who suffered heart attacks, strokes, blood clots and other serious cardiovascular events, allegedly due to their use of low testosterone treatments.

New York, New York (PRWEB) September 04, 2014

As testosterone lawsuit (http://www.drugbot.com/testosterone/lawsuit/) filings grow in courts around the U.S., Bernstein Liebhard LLP notes that the results of a review conducted by the U.S. Food & Drug Administration (FDA) are casting doubt on the purported benefits of low testosterone therapy. According to a document posted on the agencys website, millions of men take these medications to combat fatigue, low libido and other symptoms of aging. However, the FDA found little evidence to support their use in most men, and stated that the need to replace testosterone in these older men remains debatable.*

Our Firm is evaluating a number of testosterone treatment lawsuits on behalf of men who allegedly suffered heart attacks, strokes and blood clots due to their use of AndroGel and other testosterone replacement products. We have been monitoring the FDAs ongoing review very closely, says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free legal reviews to men who may have been harmed by testosterone replacement therapy.

Testosterone Treatment Lawsuits
Prescription testosterone therapies are approved to treat men who suffer from low testosterone levels due to an underlying medical issue. Medications in this class include:**

  •     Axiron
  •     AndroDerm
  •     AndroGel
  •     Bio-T Gel
  •     Delatestryl
  •     Depo-Testosterone
  •     Foresta
  •     Striant
  •     Testopel
  •     Testim

The FDAs report was prepared in advance of an advisory panel meeting the agency will convene on September 17th. While the meeting will focus on the cardiovascular risks possibly associated with the drugs, panel members will also be asked whether prescribing information on testosterone treatments should be revised to focus on a narrower selection of patients.***

The FDA announced it was reviewing the heart risks linked to the use of low testosterone therapy in January. The agency was prompted to act by the publication of two studies which indicated that older men, as well as those with pre-existing heart disease, were more likely to suffer heart attacks, strokes or death if they were using testosterone medications.

Since announcing its review, dozens of men have filed low testosterone lawsuits that seek compensation for heart problems allegedly caused by AndroGel and similar drugs. According to court documents, more than 170 such claims are currently pending in a multidistrict litigation now underway in U.S. District Court, Northern District of Illinois. Among other things, plaintiffs accuse the manufacturers of testosterone replacement medications of failing to warn doctors and patients that their use could increase the risk for heart attacks, strokes and other life-threatening cardiovascular events. (In re: Testosterone Replacement Therapy Product Liability Litigation - MDL No. 2545)

Men who allegedly experienced life-threatening heart events due to low testosterone therapy may be entitled to compensation for their injury-related damages, including medical bills, lost wages, pain and suffering, and more. Learn more about filing a testosterone treatment lawsuit by visiting Bernstein Liebhard LLPs website, or calling the Firm today at 800-511-5092.

*fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/reproductivehealthdrugsadvisorycommittee/ucm348090.pdf, FDA, September 3, 2014
**accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&searchTerm=testosterone&Search_Button=Submit, FDA
***foxnews.com/health/2014/09/03/fda-little-evidence-to-support-testosterone-drugs/, FDA, Associated Press, September 3, 2014

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.drugbot.com
https://plus.google.com/115936073311125306742?rel=author

For the original version on PRWeb visit: http://www.prweb.com/releases/testosterone-lawsuit/testosterone-heart-attack/prweb12144676.htm

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.